Recent developments include the Q1 2026 earnings release reporting a net loss and revenue performance, ongoing clinical trial progress, and continued execution of the stock repurchase program.

• Fulgent reported a net loss for Q1 2026 and provided an earnings transcript detailing operational and financial results [N1].
• The company reported Q1 2026 revenue performance with a net loss, highlighting ongoing investments in clinical trials and laboratory services growth [N2].
• Clinical trials for therapeutic candidates FID-007 and FID-022 continue with patient enrollment and data updates discussed in recent earnings calls [N1].
• Fulgent continues to execute its stock repurchase program, repurchasing shares in Q1 2026 and maintaining available authorization [N6].

Fulgent's integrated technology platform and AI-driven digital pathology capabilities enable rapid development and deployment of a wide range of diagnostic tests, supporting scalability and cost efficiency. The therapeutic development segment's novel nanoencapsulation platform has potential to improve cancer drug delivery and safety profiles, with ongoing clinical trials advancing product candidates. The company's strong patent portfolio and strategic acquisitions, such as ANP, enhance its innovation pipeline. Continued investments in sales and marketing and expansion of the customer base may support revenue growth and diversification, reducing customer concentration risk.

Fulgent faces intense competition from numerous established and emerging diagnostic and therapeutic companies with greater financial and operational resources, which may limit market share growth. Revenue concentration in a single large laboratory customer poses risk, especially as this customer has begun internalizing testing, leading to anticipated revenue declines. The therapeutic development business is in early clinical stages with inherent risks of trial outcomes and regulatory approvals. Dependence on limited suppliers for critical laboratory equipment and reagents could disrupt operations. The company has reported net losses and operating expenses that may pressure financial performance and liquidity.

Fulgent Genetics' moat is supported by its proprietary technology platform that integrates AI, proprietary gene probes, and laboratory information management systems enabling a broad, scalable, and affordable test menu. Its investment in digital pathology and nano-drug delivery technology with a robust patent portfolio provides competitive differentiation. The company's established laboratory services infrastructure with CLIA-licensed labs and a diverse customer base, combined with ongoing clinical development of novel therapeutic candidates, further strengthens its competitive position. However, the company faces significant competition from larger, well-established diagnostic and pharmaceutical companies with greater resources and market penetration.

• Customer Concentration Risk: One large laboratory customer accounted for 22% of revenue in 2025, and this customer has begun performing tests internally, which may reduce future revenue from this source.
• Competitive Pressure: The company operates in highly competitive markets with numerous established and emerging companies that have greater resources and market presence.
• Clinical Development Risk: Therapeutic development candidates are in early clinical trial phases with inherent risks related to safety, efficacy, regulatory approval, and commercialization.
• Supplier Dependence: Fulgent relies on a limited number of suppliers for key laboratory reagents and equipment, including sole supplier relationships, which could disrupt operations if supply issues arise.
• Financial Performance and Liquidity: The company has reported net losses and significant operating expenses, with ongoing investments in clinical trials and business growth that may impact cash flow and require capital raising.

• Fulgent Genetics, Inc. operates two main business segments: a laboratory services business and a therapeutic development business focused on cancer treatments using a novel nanoencapsulation and targeted therapy platform [S1].
• The laboratory services business offers comprehensive anatomic pathology testing services and precision diagnostics including next-generation sequencing (NGS) for biopharma research and clinical tests for rare diseases, hereditary cancer, reproductive health, and oncology [S1].
• The company has invested in digital pathology using AI technology to digitize specimen slides, enhancing efficiency and scalability [S1].
• Fulgent's therapeutic development business, acquired in 2022, focuses on nano-drug delivery technology for water insoluble or poorly soluble drugs, aiming to improve pharmacokinetic profiles and safety of cancer therapeutics [S1].
• Clinical trials are ongoing for product candidates FID-007 and FID-022, with Phase 1/1b and Phase 2 trials underway in the U.S. for various cancers including head & neck, pancreatic, and colon cancers [S1].
• The company has a proprietary technology platform including gene probes, AI learning software, and laboratory information management systems supporting a broad test menu and rapid test development [S1].
• Fulgent's laboratory services customers are classified by payor types: insurance, institutional (hospitals, labs, government bodies), and patients paying directly; one large customer accounted for 22% of revenue in 2025 [S1].
• The company faces competition from numerous established and emerging companies in pathology, genetic, and diagnostic testing, including Ambry Genetics, LabCorp, Myriad Genetics, Quest Diagnostics, and others [S1].
• Fulgent relies on a limited number of suppliers for key laboratory reagents and equipment, including Illumina as sole supplier of next-generation sequencers and associated reagents [S1].
• The company has a stock repurchase program authorized for $250 million with $91 million remaining as of May 1, 2026 [S2].
• As of March 31, 2026, Fulgent had $23.4 million in cash and equivalents, $479 million in current assets, $90.1 million in current liabilities, a current ratio of 5.31, and a cash ratio of 0.56 [S2].
• For the quarter ended March 31, 2026, the company reported a net loss of $24.8 million and operating cash flow of $7.1 million [S2].
• Revenue for the year ended December 31, 2025 was $322.7 million, with gross profit of $130.9 million and operating loss of $91.1 million [S1].
• Research and development expenses were $53.9 million in 2025, reflecting investment in clinical trials and therapeutic development [S1].
• The company’s long-term vision is to transform from a diagnostic business into a fully integrated precision medicine company [S1].
• Fulgent has a portfolio of over 20 issued or allowed patents and over 10 active patent applications related to its nano-drug delivery platform, with patent protection extending to 2034 and beyond [S1].
• The company’s largest laboratory customer began performing tests internally in late 2025, leading to anticipated revenue decline from this customer in 2026 [S1].
• Fulgent’s therapeutic development segment includes the acquisition of ANP, which contributes licensed technologies and manufacturing agreements [S1].
• The company’s financial disclosures emphasize liquidity strength and ongoing investments in clinical trials and laboratory services growth [S2].
• Fulgent’s sales and marketing efforts include internal teams and a network of U.S. field-based sales representatives, with recent investments to expand and restructure these teams [S1].